Fluoroquinolones, which target type II topoisomerases in bacteria, are one of the most widely prescribed antibacterials in the world; however, resistance is on the rise. My project focuses on characterizing two new classes of antibacterials that target type II topoisomerases in bacteria: Novel Bacterial Topoisomerase Inhibitors and Mycobacterium tuberculosis gyrase inhibitors. My work will aid in antibacterial drug development to help combat fluoroquinolone resistance in a wide range of bacteria including, Escherichia coli, Neisseria gonorrheoae, and Mycobacterium tuberculosis.
Graduate Student, Osheroff laboratory
Pharm.D., Lipscomb University (2014)
BA, Reinhardt College (2010)